With advances in systemic therapy for HCC, several treatments are now available for patients who experienced sorafenib treatment failure. This is the first study that compared the effectiveness of regorafenib and nivolumab in those patients. Nivolumab was associated with improved overall survival with a better objective response rate compared to regorafenib. The safety profiles were similar between the treatments, even though the patients treated with nivolumab were more likely to be with advanced liver disease compared to patients treated with regorafenib at baseline.
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INTRODUCTION
============

Hepatocellular carcinoma (HCC) is estimated to be the sixth most commonly diagnosed cancer and the fourth major cause of cancer-related mortality worldwide, with 841,000 new cases and 782,000 deaths annually \[[@b1-cmh-2019-0049n]\]. Despite the efforts to improve public health, the age-standardized incidence rate is increasing in countries with a high socio-demographic index \[[@b2-cmh-2019-0049n]\].

Although sorafenib has been shown to improve overall survival (OS) of patients with advanced HCC, the prolongation of survival is modest \[[@b3-cmh-2019-0049n]\]. Recently, several therapeutic agents have been tested in patients with HCC who have progressed during sorafenib treatment or who were intolerant to sorafenib \[[@b4-cmh-2019-0049n]-[@b8-cmh-2019-0049n]\]. In a placebo-controlled phase 3 study (RESORCE trial) in patients who had disease progression after sorafenib treatment, regorafenib, an oral multikinase inhibitor, showed improved OS \[[@b5-cmh-2019-0049n]\]. Median OS was 10.7 months for regorafenib and 7.9 months for placebo \[[@b9-cmh-2019-0049n]\]. In a non-comparative phase 2 study with nivolumab (CheckMate 040 trial) \[[@b6-cmh-2019-0049n]\], which is a human anti-programmed cell death-1 monoclonal antibody that disrupts immune checkpoint signaling, a sub-group analysis in patients who had previously treated with sorafenib demonstrated an objective response rate of 14% and disease control rate of 55% \[[@b10-cmh-2019-0049n]\]. Moreover, the median duration of response was 19.4 months \[[@b10-cmh-2019-0049n]\], suggesting that nivolumab might offer durable tumor responses. Based on these promising results, nivolumab is currently available in several countries, including the United States and Korea, for the treatment of advanced HCC after sorafenib failure.

Though regorafenib and nivolumab have been proven effective in pivotal clinical trials, study results in real-world clinical practice are limited \[[@b11-cmh-2019-0049n]-[@b15-cmh-2019-0049n]\]. In addition, a direct comparison of the efficacy of regorafenib and nivolumab has not been conducted to date. As sorafenib failed patients raised importance in clinical practice, we also included sorafenib intolerant patients. In this study, we aimed to evaluate and compare the effectiveness of regorafenib versus nivolumab in patients with HCC who had failed sorafenib treatment.

PATIENTS AND METHODS
====================

Study population
----------------

In this retrospective cohort study, we included consecutive HCC patients who had experienced disease progression or intolerance during sorafenib treatment and received regorafenib or nivolumab thereafter between July 1, 2015 and October 31, 2018 at Seoul National University Hospital (Seoul, Korea) ([Fig. 1](#f1-cmh-2019-0049n){ref-type="fig"}). The study conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Hospital. The requirement to obtain informed consent was waived because existing administrative and clinical data were obtained from the electronic databases and analyzed retrospectively.

We included patients who met all of the following inclusion criteria: 1) were at least 18 years old; 2) had received regorafenib or nivolumab treatment after sorafenib failure; and 3) HCC was radiologically or histologically confirmed according to American Association for the Study of Liver Disease criteria, with measurable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Patients were excluded from the study if any of following exclusion criteria met: 1) received prior immune-targeted therapy; 2) were participating in clinical trials; 3) prior liver transplantation; 4) unclear history of sorafenib treatment; and 5) had a concurrent malignancy other than HCC.

Treatment
---------

The clinician comprehensively assessed the clinical situation of the patient, including side effects during the previous sorafenib treatment and residual liver function to select the subsequent treatment after sorafenib failure. The initial dose of regorafenib was 160 mg once daily for the first 21 days of each 28-day cycle. Regorafenib dose adjustment by the amount of 40 mg or transient interruption (\<14 days) owing to drug-related toxicity was allowed. Nivolumab was administered intravenously every 2 weeks at a dose of 3 mg/kg. The treatments were continued until disease progression, intolerable toxicity, patient refusal of further treatment, or death from any cause.

Evaluation
----------

Baseline demographics and clinical characteristics were summarized by treatment group. It has been reported that the prognosis of patients with HCC depends on both residual liver function and the extent of the tumor \[[@b16-cmh-2019-0049n]-[@b18-cmh-2019-0049n]\]. Child-Pugh classification and standard liver function tests were used to evaluate remaining liver function. Clinically significant portal hypertension, defined by a hepatic venous pressure gradient ≥10 mmHg, was estimated by evidence of overt clinical decompensation (i.e., ascites, varices, or hepatic encephalopathy) or presence of splenomegaly with thrombocytopenia (platelet count \<150,000/mm^3^) \[[@b19-cmh-2019-0049n]\]. Pretreatment intrahepatic tumor burden and extrahepatic spread were assessed based on an imaging study prior to treatment initiation. A model to predict tumor recurrence after living donor liver transplantation score ($= 11 \times \sqrt{{protein}~{induced}~{by}~{vitamin}~K~{absence} - {II}}~ + ~2~ \times \sqrt{{alpha} - {etoprotein}~\left\lbrack {AFP} \right\rbrack}$), which was developed and validated previously to have prognostic value in patients undergoing liver transplantation for HCC was calculated for the individual patient and included in the further analyses \[[@b20-cmh-2019-0049n],[@b21-cmh-2019-0049n]\].

Clinical outcome measures
-------------------------

The date of the first regorafenib or nivolumab administration was assigned as the index date. The primary endpoint was OS, defined as time from the index date to death from any cause. For patients who switched to the other treatment (i.e., regorafenib after nivolumab or nivolumab after regorafenib), the follow-up was censored at the date of initiation of the subsequent treatment. Secondary endpoints were time to progression (TTP) defined as time from the index date to radiologic progression, objective response rate, duration of response, disease control rate. To evaluate radiologic response, two independent radiologists reviewed the images (abdomen computed tomography or magnetic resonance imaging), and the clinicians read the same images independently based on modified RECIST (mRECIST) \[[@b22-cmh-2019-0049n]\]. Every patient underwent scheduled imaging follow-up every 2--3 months. Considering insufficient drug exposure, imaging studies within 4 weeks of treatment initiation were precluded for the assessment of tumor response. Subgroup analyses were conducted for the primary and secondary endpoints according to baseline characteristics. Treatment-related toxicities leading to premature discontinuation of the treatment before the documentation of disease progression were investigated.

Statistical analyses
--------------------

Baseline demographic and clinical characteristics were compared between treatment groups. For group-wise comparisons, the independent samples t-test was used for continuous variables and either the chi-square test or the Fischer's exact test was applied for categorical variables.

The Kaplan-Meier method was used for analyses of OS and TTP. Differences between treatment groups were verified by log-rank test. To investigate whether results were confounded by other risk factors for OS or TTP, we used the multivariable Cox regression analysis. Variables in the multivariable analyses were selected using stepwise regression with the forward selection method. The objective response rate and disease control rate in each group were compared using the Cochran-Mantel-Haenszel test. Inverse probability treatment weighting (IPTW) based on the propensity score was applied to mitigate baseline differences between the groups \[[@b23-cmh-2019-0049n],[@b24-cmh-2019-0049n]\]. The propensity score for each patient was calculated using a logistic regression model using baseline characteristics, such as age, Child-Pugh score, and tumor stage. Moreover, we employed weighted Cox proportional hazards regression model to identify the treatment effect on OS and TTP.

All statistical analyses were performed using R software (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria), and IBM SPSS Statistics version 25 (IBM Corporation, Armonk, NY, USA). A two-tailed *P* value less than 0.05 was considered statistically significant.

RESULTS
=======

Patient population
------------------

Among 150 HCC patients included in final analyses, 102 patients were treated with regorafenib and 48 received nivolumab. The baseline demographic and clinical characteristics of the study patients by the group are shown in [Table 1](#t1-cmh-2019-0049n){ref-type="table"}. The median age was 62 (interquartile range \[IQR\], 55--70) years overall, and was not significantly different between the groups (*P*=0.14). Male patients accounted for 81.3% of patients, and most study patients (82.7%) were chronically infected with hepatitis B virus. Almost all patients (96.7%) were Barcelona Clinic Liver Cancer stage C, and there was no statistical difference between the groups. While 25 patients (16.7%) had no intrahepatic tumor, \>50% of the liver was occupied with the tumor in 32 patients (21.3%) at baseline. Most patients (91.3%) were Child-Pugh class A, and the proportion of patients with Child-Pugh class B was significantly higher in the nivolumab group (*P*=0.003). Prothrombin time in international normalized ratio was significantly higher in the nivolumab group (*P*=0.002). Mean serum albumin levels were lower in the nivolumab group, but the difference was not statistically significant (*P*=0.08). Thirteen (8.7%) patients who were intolerant to sorafenib treatment were included in this study. The proportion of sorafenib-intolerant patients was higher in the nivolumab group than in the regorafenib group (14.6% vs. 5.9%).

During the follow-up period, all of the patients in the nivolumab group received prespecified fixed dose. There was only one patient (2%) who experienced treatment interruption. Sixty-five patients (64%) required dose modification or treatment interruption due to adverse events in the regorafenib group. Excluding treatment delays or interruptions, 60 patients (59%) received full dose without dose reduction, and 22 patients (22%) received reduced dose (\<120 mg) of regorafenib.

OS
--

At the cutoff date for the final analysis (January 15, 2019), the median duration of follow-up of the entire cohort was 5.0 months (IQR, 2.9--7.5): 4.3 months (IQR, 2.9--6.6) for the regorafenib group and 5.2 months (IQR, 3.1--9.7) for the nivolumab group. Overall, 65 patients (43.3%) died during the follow-up period: 38 (37.3%) of 102 patients in the regorafenib group and 27 (56.3%) of 48 patients in the nivolumab group. Median OS was 5.9 months (95% confidence interval \[CI\], 3.2--18.1) in the nivolumab group and 6.9 months (95% CI, 3.5--13.1) months in the regorafenib group (*P*=0.77 by log-rank test) ([Fig. 2A](#f2-cmh-2019-0049n){ref-type="fig"}). In the multivariable analysis, treatment with nivolumab was independently associated with improved OS compared to regorafenib after adjusting for confounding factors, including Child-Pugh score and intrahepatic tumor burden (adjusted hazard ratio \[aHR\], 0.54; 95% CI, 0.30--0.96; *P*=0.04) ([Table 2](#t2-cmh-2019-0049n){ref-type="table"}). After balancing the baseline characteristics by IPTW, there was no longer any significant difference between the treatment groups ([Supplementary Table 1](#SD1-cmh-2019-0049n){ref-type="supplementary-material"}). Although there was no statistically significant difference between the groups, nivolumab was associated with better OS than regorafenib (*P*=0.11 by log-rank test) ([Fig. 3A](#f3-cmh-2019-0049n){ref-type="fig"}). Weighted Cox proportional hazards model also revealed that the nivolumab treatment was associated with improved OS (vs. regorafenib; aHR, 0.34; 95% CI, 0.18--0.65; *P*=0.001) ([Supplementary Table 2](#SD2-cmh-2019-0049n){ref-type="supplementary-material"}). Similar results were observed in additional analysis without censoring the patient who switched to the other treatment ([Supplementary Fig. 1](#SD6-cmh-2019-0049n){ref-type="supplementary-material"}).

TTP
---

During the follow-up period, tumors progressed radiologically in 91 (60.7%) of 150 patients based on mRECIST: 62 (60.8%) of 102 patients in the regorafenib group and 29 (60.4%) of 48 patients in the nivolumab group. The median TTP was not significantly different between the nivolumab group (4.0 months; 95% CI, 1.8--8.7) and the regorafenib group (3.3 months; 95% CI, 2.0--5.3) (*P*=0.40 by log-rank test) ([Fig. 2B](#f2-cmh-2019-0049n){ref-type="fig"}). In the multivariable analysis, there was no significant association with improved TTP between treatments (nivolumab vs. regorafenib; aHR, 0.81; 95% CI, 0.51--1.30; *P*=0.48) ([Table 3](#t3-cmh-2019-0049n){ref-type="table"}). After IPTW, there was no significant difference in TTP between the groups (*P*=0.30 by log-rank test) ([Fig. 3B](#f3-cmh-2019-0049n){ref-type="fig"}), and treatment group was not an independent predictor for TTP (nivolumab vs. regorafenib; aHR, 0.74; 95% CI, 0.39--1.41; *P*=0.36) ([Supplementary Table 3](#SD3-cmh-2019-0049n){ref-type="supplementary-material"}).

Overall tumor response
----------------------

No patient in either treatment group achieved a complete response. Eight (16.7%) of 48 patients in the nivolumab group and six (5.9%) of 102 patients in the regorafenib group achieved a partial response by mRECIST, and nivolumab showed significantly better objective response rate compared to regorafenib (*P*=0.041) ([Table 4](#t4-cmh-2019-0049n){ref-type="table"}). The disease control rate (i.e., the proportion of patients who had an objective response or disease stabilization) was 50.0% in the nivolumab group and 47.1% in the regorafenib group (*P*=0.58). Among the 14 patients who achieved an objective response, 10 patients did not progress during the follow-up. Median duration of response, which was evaluated for patients with tumor response, was 4.2 months (3.5--not estimable \[NE\]) in the nivolumab group and 2.7 (2.2--NE) months in the regorafenib group (*P*=0.73 by log-rank test).

Subgroup analysis
-----------------

Comparisons of outcomes between treatments were assessed among the subgroups. There was no difference in OS or TTP between the groups regarding duration of prior sorafenib treatment ([Supplementary Fig. 2](#SD7-cmh-2019-0049n){ref-type="supplementary-material"}), or Child Pugh score ([Supplementary Fig. 3](#SD8-cmh-2019-0049n){ref-type="supplementary-material"}). Further analysis according to the presence or absence of portal hypentension/macrovascular invasion, and AFP level showed no significant OS difference between the two treatment groups ([Supplementary Fig. 4](#SD9-cmh-2019-0049n){ref-type="supplementary-material"}).

Safety
------

The reasons for the drug discontinuation were assessed for the safety analysis. Eighty-three patients discontinued the treatment due to disease progression among 122 patients who discontinued the treatment ([Supplementary Table 4](#SD4-cmh-2019-0049n){ref-type="supplementary-material"}). Adverse events that caused premature drug discontinuation occurred in 24 patients (23.5%) in the regorafenib group and eight patients (16.7%) in the nivolumab group (*P*=0.34). The major cause of drug discontinuation before radiologic progression was hepatic decompensation: four (8.3%) in the nivolumab group and 10 (9.8%) in the regorafenib group (*P*=0.77). Subsequent treatments after study drug failure were assessed. The proportion of patients who received any treatments after the study drug failure in both groups was similar (*P*=0.54) ([Supplementary Table 5](#SD5-cmh-2019-0049n){ref-type="supplementary-material"}).

DISCUSSION
==========

In the current study in HCC patients who had experienced sorafenib treatment failure, nivolumab treatment was associated with improved OS compared with regorafenib treatment. The risk of all-cause mortality was reduced by 46% in patients receiving nivolumab compared to patients receiving regorafenib. Although TTP did not differ significantly between the treatments, nivolumab demonstrated a significantly better objective response rate than regorafenib. Both drugs were well tolerated during the treatment period; however, adverse events leading to drug discontinuation before radiologic disease progression were more frequent in patients receiving regorafenib.

To date, this is the first study in a real-world setting comparing the effectiveness of regorafenib and nivolumab treatments in HCC patients who previously failed sorafenib treatment. Nivolumab was more effective than regorafenib in terms of OS. While median OS was longer in patients treated with regorafenib (6.9 months) versus nivolumab (5.9 months), nivolumab showed a significant association with improved OS after adjusting for confounders. In the present study, patients with higher Child-Pugh scores at baseline, an independent predictive factor for poor OS, were more likely to be treated with nivolumab. To minimize treatment selection bias, we adopted IPTW in addition to multivariable analyses, and the association of nivolumab with prolonged OS was confirmed.

The higher objective response rate with nivolumab might confer its association with improved OS compared with regorafenib. The objective response rate with nivolumab was 16.7% in the current study, a finding that is consistent with previous studies reporting objective response rates of 14.3--16.7% \[[@b10-cmh-2019-0049n],[@b14-cmh-2019-0049n],[@b25-cmh-2019-0049n]\]. However, the objective response rate with regorafenib (5.9%) was lower compared to the previous studies (10.0--10.6%) \[[@b5-cmh-2019-0049n],[@b15-cmh-2019-0049n]\]. In the RESORCE trial, the objective response rate was 10.6%, and 68% of patients experienced drug interruption or dose modification during the treatment \[[@b5-cmh-2019-0049n]\]. The rates of treatment interruption or dose modification of patients receiving regorafenib in our present study was similar to those in the RESORCE trial. Dose intensity was also comparable. Scheduled imaging was performed every 6 weeks at the beginning of treatment in the RESORCE trial. However the imaging intervals were variable ranged from 2 to 3 months in the current retrospective study, which may have affected the tumor response. The duration of response was longer in patients treated with nivolumab than in patients treated with regorafenib, even though the difference was not statistically significant. This finding is consistent with the results of the CheckMate 040 trial which reported sustained tumor response with nivolumab in HCC patients \[[@b6-cmh-2019-0049n],[@b10-cmh-2019-0049n]\]. Further studies with sufficient observational periods are warranted to demonstrate a statistically significant difference in the duration of response between nivolumab and regorafenib.

The median OS with nivolumab (5.9 months) and regorafenib (6.9 months) was shorter than reported in the corresponding results from the pivotal trials. Median OS with regorafenib was 10.7 months in the RESORCE trial, and median OS with nivolumab was 15.1 months in the sorafenib progressor cohort in the CheckMate 040 trial \[[@b9-cmh-2019-0049n],[@b10-cmh-2019-0049n]\]. In contrast, recent real-world evidence studies evaluating the efficacy of nivolumab reported that median OS with nivolumab ranged from \<2 months to 11.0 months \[[@b11-cmh-2019-0049n]-[@b14-cmh-2019-0049n]\]. Considering the major causes of death of advanced HCC patients were intrahepatic tumor progression and complications of cirrhosis, the discrepancy between the results of clinical trials and real-world studies can be explained by the differences in baseline characteristics of the study population \[[@b16-cmh-2019-0049n],[@b18-cmh-2019-0049n]\]. However, even though regorafenib treatment demonstrated efficacy over placebo in prolonging OS after sorafenib failure in the RESORCE trial, and the ability of nivolumab to improve OS compared to regorafenib was demonstrated in the current study, survival gain with nivolumab treatment is still unsatisfactory. Recently, the efficacy of combination treatments with immune checkpoint inhibitors plus molecular targeted agents in advanced HCC patients was evaluated in phase 1b trials \[[@b26-cmh-2019-0049n],[@b27-cmh-2019-0049n]\]. Promising results of objective response rates over 30--40% were reported; however, safety-related issues need to be clarified. In a recent study, it was reported that less than half of patients were eligible for subsequent systemic therapy after sorafenib failure due to impaired hepatic function \[[@b28-cmh-2019-0049n]\]. Therefore, it is crucial to establish a treatment strategy maximizing efficacy without compromising safety.

Despite the unsatisfactory effects, it is noteworthy that small portion of patients did achieve prolonged DOR more than a year and even complete responses with regorafenib or nivolumab treatment. HCC patients who experienced sorafenib failure are heterogenous in terms of varying prior treatments \[[@b29-cmh-2019-0049n]\], different tumor characteristics, and degrees of liver fibrosis, but biomarker based treatment is limited due to the risk of liver biopsy. Thus, treatment strategy of those patients is mainly dependent on clinical judgment. Previous study by Lee et al. \[[@b30-cmh-2019-0049n]\] estimated survival and prognosis of patients who experienced sorafenib failure based on clinical parameters. In our study, male sex, extensive intraheptatic tumor burden and higher Child-Pugh score at the time of sorafenib failure were identified as poor survival markers.

The safety profiles of regorafenib and nivolumab in the present study were generally consistent with those reported in previous studies \[[@b5-cmh-2019-0049n],[@b6-cmh-2019-0049n],[@b13-cmh-2019-0049n]-[@b15-cmh-2019-0049n],[@b25-cmh-2019-0049n]\]. Whilst both treatments showed comparable safety in terms of drug discontinuation rate, the proportion of patients with impaired hepatic function was significantly higher among patients receiving nivolumab compared to regorafenib at baseline. Furthermore, three of four patients who discontinued nivolumab treatment due to hepatic decompensation had extensive intrahepatic tumor burden (\>50%) at the start of treatment. Therefore, the possibility of overestimating the hepatotoxicity of nivolumab should be accounted for. Previous studies including Child-Pugh class B patients with HCC showed similar safety profile of nivolumab between Child-Pugh class A and Child-Pugh Class B subgroups \[[@b14-cmh-2019-0049n],[@b25-cmh-2019-0049n]\]. Moreover, one patient with Child-Pugh class C disease at baseline showed complete response during the treatment with nivolumab in a small study involving 14 HCC patients \[[@b31-cmh-2019-0049n]\]. The safety of nivolumab in patients with hepatic impairment needs to be validated in future studies.

Our study has several limitations to be considered. First, in terms of tumor response assessment, the follow-up intervals for imaging studies varied among the study patients. However, since this issue results from the nature of the retrospective study design and was not limited to either regorafenib or nivolumab treatment, the effect on the efficacy comparison is thought to be negligible. Second, although the major adverse events leading to treatment discontinuation were analyzed, it was impossible to obtain accurate information about adverse events that occurred during the study period. Further, well-designed prospective studies are needed to verify the safety in real-world clinical practice. Third, because we assessed the tumor response based on mRECIST, pseudoprogression, a unique pattern of tumor response with immunotherapy, was not considered for the patients receiving nivolumab. Though the rate of pseudoprogression is known to be rare (\<10%) across tumor types \[[@b32-cmh-2019-0049n]\], there have been reports of prolonged response to immune checkpoint inhibitors after pseudoprogression in HCC patients \[[@b33-cmh-2019-0049n],[@b34-cmh-2019-0049n]\]. In the era of cancer immunotherapy, tumor response evaluation based on immune RECIST should be further validated in HCC patients \[[@b35-cmh-2019-0049n]\].

In the current study in patients with HCC who previously failed sorafenib treatment, subsequent nivolumab treatment may improve OS over regorafenib treatment and also demonstrated a higher objective response rate. Since nivolumab, an immune modulator, has a completely different mechanism of action and side effect profile from sorafenib, treatment with nivolumab may be a potential therapeutic option for the treatment of HCC after sorafenib failure, particularly in patients showing sorafenib intolerance. Both regorafenib and nivolumab were well tolerated overall. Additional studies investigating the effectiveness of nivolumab in combination with other treatments are warranted in consideration of its efficacy and safety.
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Baseline characteristics by the treatment group after IPTW
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Univariable and multivariable Cox regression analysis for OS after IPTW

###### 

Univariable and multivariable Cox regression analysis for TTP after IPTW
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Rates and reasons for premature discontinuation of the study drug at cutoff date

###### 

Treatment after discontinuation of study drug

###### 

OS analysis without censoring patients who switched to the other treatment before (A) and after IPTW (B). CI, confidence interval; OS, overall survival; IPTW, inverse probability treatment weighting.

###### 

A subgroup analysis of OS (A, B) and TTP (C, D) regarding duration of sorafenib treatment. OS, overall survival; TTP, time to progression.

###### 

A subgroup analysis of OS (A, B) and TTP (C, D) regarding Child-Pugh score. OS, overall survival; TTP, time to progression.

###### 

Subgroup analyses of OS, regarding presence of portal HTN (A, B), AFP level (C, D), and presence of macrovascular tumor invasion (E, F). portal HTN, portal hypertension; AFP, alpha-fetoprotein; OS, overall survival.
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aHR

:   adjusted hazard ratio
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:   modified Response Evaluation Criteria in Solid Tumors

NE
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:   overall survival
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###### 

Baseline characteristics by treatment group

  Characteristic                                                                    Overall (n=150)          Group                    *P*-value                
  --------------------------------------------------------------------------------- ------------------------ ------------------------ ------------------------ ---------
  Age (years)                                                                       62 (55--70)              62 (56--71)              61 (54--67)              0.14
  Male                                                                              122 (81.3)               83 (81.4)                39 (81.2)                0.99
  HCC etiology                                                                                                                                                 0.44
   HBV                                                                              124 (82.7)               86 (84.3)                38 (79.2)                
   Others                                                                           26 (17.3)                16 (15.7)                10 (20.8)                
  Child-Pugh score                                                                                                                                             0.003
   5                                                                                86 (57.3)                66 (64.7)                20 (41.7)                
   6                                                                                51 (34.0)                32 (31.4)                19 (39.6)                
   7--9                                                                             13 (8.7)                 4 (3.9)                  9 (18.8)                 
  Vascular invasion                                                                 66 (44.0)                42 (41.2)                24 (50.0)                0.31
  Biliary invasion                                                                  7 (4.7)                  5 (4.9)                  2 (4.2)                  0.84
  Intrahepatic tumor burden                                                                                                                                    0.40
   None                                                                             25 (16.7)                19 (18.6)                6 (12.5)                 
   \<50%                                                                            93 (62.0)                64 (62.7)                29 (60.4)                
   ≥50%                                                                             32 (21.3)                19 (18.6)                13 (27.1)                
  Extrahepatic metastases                                                           120 (80.0)               79 (77.5)                41 (85.4)                0.26
   Lymph node                                                                       54 (36.0)                37 (36.3)                17 (35.4)                
   Lung                                                                             77 (51.3)                46 (45.1)                31 (64.6)                
   Bone                                                                             32 (21.3)                21 (20.6)                11 (22.9)                
   Peritoneum                                                                       24 (16.0)                16 (15.7)                8 (16.7)                 
   Others                                                                           3 (2.0)                  1 (1.0)                  2 (4.2)                  
  Portal hypertension                                                               64 (42.7)                42 (41.2)                22 (45.8)                0.59
  BCLC stage                                                                                                                                                   0.56
   B                                                                                5 (3.3)                  4 (3.9)                  1 (2.1)                  
   C                                                                                145 (96.7)               98 (96.1)                47 (97.9)                
  Laboratory data                                                                                                                                              
   Albumin (g/dL)                                                                   3.7 (3.3--4.0)           3.8 (3.4--4.1)           3.7 (3.2--3.9)           0.08
   Total bilirubin (mg/dL)                                                          1.0 (0.7--1.4)           1.0 (0.7--1.3)           1.1 (0.7--1.7)           0.29
   AST (IU/L)                                                                       49 (33--80)              45 (32--77)              60 (39--90)              0.16
   ALT (IU/L)                                                                       37 (22--59)              37 (22--57)              38 (23--60)              0.42
   ALP (IU/L)                                                                       138 (88--220)            133 (87--220)            144 (92--212)            0.88
   Creatinine (mg/dL)                                                               0.81 (0.68--0.93)        0.82 (0.68--0.93)        0.80 (0.69--0.93)        0.44
   Platelet count (×109/L)                                                          154 (105--218)           164 (107--228)           149 (101--204)           0.28
   INR                                                                              1.08 (1.02--1.15)        1.06 (1.00--1.12)        1.10 (1.04--1.21)        0.002
   AFP (ng/mL)                                                                      431 (12.5--4,185.0)      338.0 (11.9--3,799.3)    760.0 (18.4--4,665.0)    0.90
   PIVKA (mAU/mL)                                                                   1,453 (135--8,898)       1,365 (149--8,699)       1,803 (107--10,545)      0.48
   MoRAL                                                                            570.6 (205.1--1,254.3)   570.6 (240.1--1,224.0)   559.5 (234.2--1,276.5)   0.62
  Intolerant to sorafenib                                                           13 (8.7)                 6 (5.9)                  7 (14.6)                 0.08
  Duration of sorafenib^[\*](#tfn1-cmh-2019-0049n){ref-type="table-fn"}^ (months)   2.8 (2.0--4.7)           3.0 (2.3--6.2)           2.5 (1.4--3.1)           \<0.001
  Time interval between sorafenib and treatment (months)                            1.2 (0.0--4.7)           0.9 (0.0--4.6)           1.8 (0.3--5.8)           0.89

Values are presented as median (interquartile range) or number (%) of patients.

HCC, hepatocellular carcinoma; HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; INR, international normalized ratio; AFP, alpha-fetoprotein; PIVKA, protein induced by vitamin K absence or antagonist; MoRAL, model to predict tumor recurrence after living donor liver transplantation.

Assessed for patients who progressed after sorafenib (n=136).

###### 

Univariable and multivariable Cox regression analyses for overall survival

  Characteristic                          Univariable analysis    Multivariable analysis                           
  --------------------------------------- ----------------------- ------------------------ ----------------------- ---------
  Nivolumab (vs. regorafenib)             1.081 (0.644--1.813)    0.77                     0.536 (0.300--0.957)    0.04
  Age (per year increase)                 0.987 (0.966--1.009)    0.24                                             
  Male sex (vs. female)                   2.313 (1.052--5.086)    0.04                     2.587 (1.140--5.872)    0.02
  Etiology of HCC, HBV (vs. others)       1.572 (0.775--3.185)    0.21                                             
  Child-Pugh score                                                                                                 
   5                                      1 (reference)           \<0.001                  1 (reference)           \<0.001
   6                                      3.532 (2.009--6.210)    \<0.001                  3.458 (1.912--6.252)    \<0.001
   7--9                                   6.264 (2.926--13.410)   \<0.001                  5.195 (2.073--13.018)   \<0.001
  Vascular invasion, yes (vs. no)         2.104 (1.275--3.471)    0.004                                            
  Biliary invasion, yes (vs. no)          3.049 (1.205--7.718)    0.02                                             
  Intrahepatic tumor burden                                       \<0.001                                          0.01
   None                                   1 (reference)                                    1 (reference)           
   \<50%                                  2.024 (0.847--4.833)    0.11                     1.488 (0.595--3.722)    0.40
   ≥50%                                   7.148 (2.853--17.905)   \<0.001                  2.801 (1.019--7.703)    0.046
  Extrahepatic metastasis, yes (vs. no)   0.522 (0.296--0.919)    0.02                                             
  Portal hypertension, yes (vs. no)       1.503 (0.919--2.458)    0.10                                             
  BCLC stage C (vs. B)                    0.913 (0.222--3.759)    0.90                                             
  AST (per IU/L)                          1.012 (1.008--1.016)    \<0.001                  1.007 (1.002--1.012)    0.004
  ALT (per IU/L)                          1.008 (1.004--1.012)    \<0.001                                          
  ALP (per IU/L)                          1.003 (1.002--1.004)    \<0.001                                          
  Creatinine (per mg/dL)                  0.359 (0.113--1.142)    0.08                                             
  Platelet count (per ×10^9^/L)           1.002 (1.000--1.005)    0.09                                             
  AFP ≥400 ng/mL                          1.359 (0.828--2.232)    0.23                                             
  PIVKA ≥1,000 mAU/mL                     2.842 (1.622--4.980)    \<0.001                                          
  MoRAL ≥314.8                            3.056 (1.677--5.569)    \<0.001                  1.897 (0.999--3.602)    0.05

*P* values were determined using Cox proportional hazards regression models. *P*\<0.05 indicated a significant difference.

HR, hazards ratio; CI, confidence interval; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AFP, alpha-fetoprotein; PIVKA, protein induced by vitamin K absence or antagonist; MoRAL, model to predict tumor recurrence after living donor liver transplantation.

###### 

Univariable and multivariable Cox regression analyses for time to progression

  Characteristic                          Univariable analysis   Multivariable analysis                          
  --------------------------------------- ---------------------- ------------------------ ---------------------- -------
  Nivolumab (vs. regorafenib)             0.824 (0.522--1.299)   0.40                     0.812 (0.509--1.297)   0.48
  Age (per year increase)                 0.985 (0.964--1.006)   0.15                                            
  Male sex (vs. female)                   1.375 (0.809--2.335)   0.24                                            
  Etiology of HCC, HBV (vs. others)       1.458 (0.792--2.681)   0.23                                            
  Child-Pugh score                                               0.20                                            
   5                                      1 (reference)                                                          
   6                                      1.502 (0.954--2.366)   0.08                                            
   7--9                                   0.972 (0.351--2.689)   0.96                                            
  Vascular invasion, yes (vs. no)         1.016 (0.663--1.558)   0.94                                            
  Biliary invasion, yes (vs. no)          1.666 (0.672--4.131)   0.27                                            
  Intrahepatic tumor burden                                      0.04                                            
   None                                   1 (reference)                                                          
   \<50%                                  1.098 (0.642--1.878)   0.73                                            
   ≥50%                                   2.067 (1.073--3.982)   0.03                                            
  Extrahepatic metastasis, yes (vs. no)   0.810 (0.475--1.379)   0.44                                            
  Portal hypertension, yes (vs. no)       1.332 (0.869--2.041)   0.19                                            
  BCLC stage C (vs. B)                    0.305 (0.109--0.856)   0.02                                            
  AST (per IU/L)                          1.006 (1.001--1.011)   0.01                                            
  ALT (per IU/L)                          1.003 (0.998--1.009)   0.23                                            
  ALP (per IU/L)                          1.002 (1.001--1.003)   0.001                    1.002 (1.001--1.003)   0.002
  Creatinine (per mg/dL)                  0.589 (0.230--1.510)   0.27                                            
  Platelet count (per ×10^9^/L)           1.003 (1.001--1.006)   0.004                    1.003 (1.001--1.005)   0.01
  AFP ≥400 ng/mL                          1.063 (0.703--1.608)   0.77                                            
  PIVKA ≥1,000 mAU/mL                     1.217 (0.803--1.846)   0.36                                            
  MoRAL ≥314.8                            1.210 (0.794--1.844)   0.37                                            

*P* values were determined using Cox proportional hazards regression models. *P*\<0.05 indicated a significant difference.

HR, hazards ratio; CI, confidence interval; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AFP, alpha-fetoprotein; PIVKA, protein induced by vitamin K absence or antagonist; MoRAL, model to predict tumor recurrence after living donor liver transplantation.

###### 

Best overall response by treatment group

                                                                           Regorafenib (n=102)   Nivolumab (n=48)
  ------------------------------------------------------------------------ --------------------- ------------------
  Best overall response^[\*](#tfn2-cmh-2019-0049n){ref-type="table-fn"}^                         
   Complete response                                                       0                     0
   Partial response                                                        6 (5.9)               8 (16.7)
   Stable disease                                                          42 (41.2)             16 (33.3)
   Progressive disease                                                     37 (36.3)             17 (35.4)
   Not assessed                                                            17 (16.7)             7 (14.6)
  Objective response^[†](#tfn3-cmh-2019-0049n){ref-type="table-fn"}^       6 (5.9)               8 (16.7)
  Disease control^[‡](#tfn4-cmh-2019-0049n){ref-type="table-fn"}^          48 (47.1)             24 (50.0)

Values are presented as number (%) of patients.

Based on radiological review using modified Response Evaluation Criteria in Solid Tumors (mRECIST) for hepatocellular carcinoma.

Two-sided *P*=0.041.

Two-sided *P*=0.58.
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